Skip to main content

Reference Datasets for 2-Treatment, 2-Sequence, 2-Period Bioequivalence Studies


It is difficult to validate statistical software used to assess bioequivalence since very few datasets with known results are in the public domain, and the few that are published are of moderate size and balanced. The purpose of this paper is therefore to introduce reference datasets of varying complexity in terms of dataset size and characteristics (balance, range, outlier presence, residual error distribution) for 2-treatment, 2-period, 2-sequence bioequivalence studies and to report their point estimates and 90% confidence intervals which companies can use to validate their installations. The results for these datasets were calculated using the commercial packages EquivTest, Kinetica, SAS and WinNonlin, and the non-commercial package R. The results of three of these packages mostly agree, but imbalance between sequences seems to provoke questionable results with one package, which illustrates well the need for proper software validation.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8


  1. European Medicines Agency, Committee for Human Medicinal Products. Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr. 2010.

  2. US Food and Drug Administration. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations. 2003.

  3. World Health Organization. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. In: Fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva, World Health Organization. WHO Technical Report Series, No. 937, 2006, Annex 7.

  4. Health Canada, Therapeutic Products Directorate. Conduct and Analysis of Comparative Bioavailability Studies. 2012.

  5. Chow S-C, Liu J-P. Design and analysis of bioavailability and bioequivalence studies. 3rd ed. Boca Raton: CRC; 2009.

    Google Scholar 

  6. International Conference on Harmonization. Statistical Principles for Clinical Trials, guideline E9. 1998.

  7. US Food and Drug Administration. Computerized Systems Used in Clinical Trials. 1999.

  8. Sauter R, Steinijans VW, Diletti E, Böhm E, Schulz H-U. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992;30:S7–30.

    PubMed  Google Scholar 

  9. Hauschke D, Steinijans V, Pigeot I. Bioequivalence studies in drug development. Methods and applications. Chichester: Wiley; 2007.

    Book  Google Scholar 

  10. Clayton D, Leslie A. The bioavailability of erythromycin stearate versus enteric-coated erythromycin base when taken immediately before or after food. J Int Med Res. 1981;9:470–7.

    PubMed  CAS  Google Scholar 

  11. Rani S, Pargal A. Bioequivalence: an overview of statistical concepts. Ind J Pharmacol. 2004;36:209–16.

    Google Scholar 

  12. Soukup M. Using R: perspectives of a FDA statistical RevieweR. Presentation at useR! conference, Iowa State University, August 8–10, 2007.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Anders Fuglsang.

Electronic supplementary material

Below is the link to the electronic supplementary material.


(TXT 0 kb)


(TXT 0 kb)


(TXT 0 kb)


(TXT 0 kb)


(TXT 0 kb)


(TXT 4 kb)


(TXT 52 kb)


(TXT 37 kb)


(RTF 47 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schütz, H., Labes, D. & Fuglsang, A. Reference Datasets for 2-Treatment, 2-Sequence, 2-Period Bioequivalence Studies. AAPS J 16, 1292–1297 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • bioequivalence
  • crossover
  • software validation